Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female participants aged ≥18 years.~* In Cohort 1, participants must have at least 25 cm\^2 of chronic plaque psoriasis (excluding the face, scalp, intertriginous areas, palms and soles).~* In Cohort 2, participants must have 0.5% to 5.0% of total BSA of chronic plaque psoriasis and at least one target plaque, of at least 9 cm\^2 in size with a TPSS ≥4 (excluding the face, scalp, intertriginous areas, palms and soles).~* Women of childbearing potential must have a negative urine pregnancy test at Screening and agree to use birth control throughout the trial.~* In good health as judged by the Investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), serum chemistry labs, hematology values, and urinalysis.~* Participants agree not to have prolonged sun exposure during the course of the study. Tanning bed use is not allowed.~* Participants are competent to sign and give informed consent and considered reliable and capable of adhering to the Protocol and visit schedule.~Exclusion Criteria:~* Participants with non-plaque forms of psoriasis (erythrodermic, guttate, pustular or palmo-plantar psoriasis) or with drug-induced psoriasis.~* Evidence of skin conditions other than psoriasis that would interfere with evaluation of the effect of the study medication.~* Pregnant or lactating women or women planning to become pregnant during the study and / or within 28 days following the last dose of study medication.~* Known allergies to excipients in ARQ-151 cream.~* Participants who cannot discontinue the use of strong P-450 cytochrome inducers or inhibitors for two weeks prior to the baseline visit and during the study period.~* Participants who are unwilling to refrain from using a tanning bed for 2 weeks before and during the study.~* Participants who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis.~* Participants with a history of chronic alcohol or drug abuse in past 6 months.~* History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to phosphodiesterase type 4 (PDE-4) inhibitors.~* Current or a history of cancer within 5 years with the exception of fully excised skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.~* Participants with active infection that requires oral or intravenous administration of antibiotics, antifungal or antiviral agents.~* Participants who are unable to communicate, read or understand language, or who display another condition which makes them unsuitable for clinical study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - ARQ-151 cream 0.5% (Type: EXPERIMENTAL): Single-dose application of ARQ-151 cream 0.5% to 25 cm\^2 of psoriatic plaque(s)
- Cohort 2 - ARQ-151 cream 0.5% (Type: EXPERIMENTAL): ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
- Cohort 2 - ARQ-151 cream 0.15% (Type: EXPERIMENTAL): ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
- Cohort 2 - ARQ-151 vehicle cream (Type: PLACEBO_COMPARATOR): Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete